PDCD1 and neoplasm: Similarly, compared to gemcitabine chemotherapy, PD-1 antibody immunotherapy demonstrated no significant difference in CD8+ T cell infiltration in tumor tissue (Fig. S3A-B), but CD4+ T cell enrichment diminished (Fig. S3 A, C) and Treg cell frequency also decreased (Fig. 6 C-D).